SEC Filings
X4 Pharmaceuticals Refinances Hercules Debt With $80 Million K2 Loan Due In 2030
The new facility pushes out a July 2027 maturity, adds a market-value cash covenant from 2027, and lets lenders convert up to $15.0 million into stock.
X4 Pharmaceuticals (XFOR) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
SEC Filings
The new facility pushes out a July 2027 maturity, adds a market-value cash covenant from 2027, and lets lenders convert up to $15.0 million into stock.
Earnings
X4 also set topline data for its pivotal 4WARD trial in the first quarter of 2028, with possible FDA approval in late 2028 or early 2029.
SEC Filings
The 8-K shows $80 million funded at closing, cash and revenue covenants, and a $15.0 million conversion option for the lender.